Literature DB >> 10932599

Laboratory tests for neuroendocrine tumours.

E Seregni1, L Ferrari, M Stivanello, L Dogliotti.   

Abstract

Neuroendocrine tumours (NETs) often have a good prognosis and have peculiar biological characteristics, among which the ability to produce and release biologically active substances. Hypersecretion of hormones, biogenic amines or growth factors often cause severe syndromes that are very debilitating. Now sensitive assays for the measurement of these substances have been developed and this has improved the possibility of patient follow-up by means of in vitro examinations. The decision about which in vitro examination to be utilised for NET management is very difficult because of the NET low incidence, the very large number of measurable hormones, the difficulty or low patient compliance for some diagnostic tests. In this review we describe the most useful laboratory tests for determining the diagnosis of NET, their prognostic significance and the clinical value of specific marker evaluation in the follow-up of the NET patient. Particular consideration has been given to biomarkers for gastroenteropancreatic and sympatho-adrenal system tumours and for prostate and breast cancers with neuroendocrine differentiation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10932599

Source DB:  PubMed          Journal:  Q J Nucl Med        ISSN: 1125-0135


  2 in total

1.  [18F]FDG-PET/CT and long-term responses to everolimus in advanced neuroendocrine neoplasia.

Authors:  M Rinzivillo; D Prosperi; F Mazzuca; L Magi; E Iannicelli; E Pilozzi; G Franchi; A Laghi; B Annibale; A Signore; F Panzuto
Journal:  J Endocrinol Invest       Date:  2020-08-07       Impact factor: 4.256

2.  Italian Association of Clinical Endocrinologists (AME) position statement: a stepwise clinical approach to the diagnosis of gastroenteropancreatic neuroendocrine neoplasms.

Authors:  Franco Grimaldi; Nicola Fazio; Roberto Attanasio; Andrea Frasoldati; Enrico Papini; Francesco Angelini; Roberto Baldelli; Debora Berretti; Sara Bianchetti; Giancarlo Bizzarri; Marco Caputo; Roberto Castello; Nadia Cremonini; Anna Crescenzi; Maria Vittoria Davì; Angela Valentina D'Elia; Antongiulio Faggiano; Stefano Pizzolitto; Annibale Versari; Michele Zini; Guido Rindi; Kjell Oberg
Journal:  J Endocrinol Invest       Date:  2014-07-20       Impact factor: 4.256

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.